Vivace Therapeutics Appoints New Leadership Ahead of Phase 3 Mesothelioma Trial

Vivace Therapeutics has strengthened its executive team as it prepares to advance VT3989, the first TEAD inhibitor entering Phase 3 clinical trials for mesothelioma treatment.

26 Aug, 11:35 — 26 Aug, 11:35

Post Share

Sources

Showing 1 of 1 sources

morningstar3d ago

Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma - Morningstar

Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma Morningstar

Read full article →

PERSPECTA

PERSPECTA

Vivace Therapeutics Appoints New Leadership Ahead of Phase 3 Mesothelioma Trial

Sources

Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma - Morningstar

Related Stories

Federal Reserve Signals Potential Rate Hikes Amid Stubborn Inflation

OpenAI Ends Partnership With SpaceX-Owned Coding Tool Cursor

College Dropout Turns Full-Time Pokémon Card Reseller With $7.8M in Sales

Temasek Backs Singapore Airlines’ Strategic Investment in Air India

PERSPECTA